Kusurinomadoguchi (5592) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
13 Nov, 2026Executive summary
H1 FY2027 revenue rose 24.2% YoY to ¥7,236m and operating income rose 19.9% to ¥1,513m; net income fell 7.1% to ¥1,505m.
Recurring sales grew across businesses; quarterly stock sales and stock gross profit reached records in Q2.
Financial highlights
H1 gross profit was ¥4,125m (+24.7% YoY), ordinary income ¥1,506m (+20.3%) and EBITDA ¥2,338m (+17.9%); stock gross profit was ¥2,220m (+34.5%).
Net income attributable to owners fell 7.1% YoY; the prior-year period benefited by ~¥600m from deferred tax asset recognition, while H1 included a ¥136.6m income-tax adjustment benefit.
Operating cash flow was ¥10,884m versus ¥1,068m a year earlier, mainly due to a ¥9,005m increase in unpaid amounts; H1-end cash and equivalents were ¥12,893m.
Outlook and guidance
FY2027 guidance unchanged: revenue ¥14,400m (+16.8%), operating income ¥3,100m (+15.6%), ordinary income ¥3,100m (+16.3%) and net income ¥3,100m (+5.0%); forecast EPS ¥270.53.
H1 progress was 50% of revenue guidance and 49% of operating, ordinary and net income guidance; annual dividend forecast remained ¥40 per share.
FY2030 targets: stock revenue of ¥20bn, operating profit of at least ¥5bn and a facility base of 100,000; priorities include software and service development, AI-enabled efficiency and growth investment.
Latest events from Kusurinomadoguchi
- Q1 FY3/2027 revenue and profit rose over 25% YoY, with net income up 61% and strategic expansion.5592
Q1 2027 - Record profit and revenue growth, with double-digit gains forecast for FY2027.5592
Q4 2026 - Record profit and revenue growth drive higher guidance and dividend, fueled by digital healthcare and acquisitions.5592
Q3 2026 - Record profit and net income driven by recurring sales growth and capital reduction effects.5592
Q2 2026 - Revenue up 28% YoY, profit growth, digital healthcare demand, and guidance maintained.5592
Q2 2025 - Q1 FY2025 revenue up 22.1% YoY, but profit fell due to higher SG&A from acquisitions.5592
Q1 2025 - Record Q3 profit and revenue drive upward revision of full-year outlook and dividend.5592
Q3 2025 - Strong profit and revenue growth, improved financials, and robust digital healthcare outlook.5592
Q4 2025 - Record Q1 revenue and profit growth with strong margins; full-year guidance unchanged.5592
Q1 2026